Biophytis announced it is convening an Extraordinary and Ordinary Shareholders' Meeting for March 30, 2023

  • Delegation to the Board of Directors to reduce the nominal value
  • Regrouping of the company’s shares
  • Renewal of Authorizations granted at the June 2022 AGM

Stanislas Veillet, CEO of Biophytis, stated: “Following COVA study positive results, we now wishe to regain the leeway and tools to refinance the company. We therefore ask shareholders to allow us to reduce the “par value” of the share within the limit of the company’s losses and for a minimum value of €0.002. This reduction in the nominal value will allow us to access the market again in an alternative or complementary way to convertible bond contracts. We also ask to regroup the shares by a maximum factor of 400. Furthermore, we call on the shareholders to renew the various resolutions relating to capital increases.”

The resolutions are published in the BALO on Wednesday February 22, 2023.